If additional glucose lowering is needed despite therapy with a long-acting GLP-1 receptor agonist, the addition of basal insulin is a reasonable option [215, 216]
Synergy Rx asks two condition multi-selects with a suicidal-thoughts checkbox and the cancer 5-year-remission threshold, but MTC and MEN2 family history are not asked anywhere in the visible flow a significant FDA-black-box gap
The choice is guided by factors like patient preferences, adherence potential, side effect tolerability, comorbidities, administration logistics, and cost-access considerations, emphasizing shared decision-making for optimal outcomes. Learn more about taking GLP-1s when you have a digestive health condition
From there, theyll work with you to decide on a safe, evidence-based plan and discuss what to expect from treatment